Search research articles
Contact Us
Filters
Showing results (71-80 of 77) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 77 results.
International Journal of Cancer
|
March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
Jens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Annals of Hematology
|
July 8, 2003
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
H Goldschmidt, P Sonneveld, F W Cremer, et al.
Oncogene
|
March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
Karène Mahtouk, Dirk Hose, Thierry Rème, et al.
Leukemia
|
March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield
I Breitkreutz, H M Lokhorst, M S Raab, et al.
Blood
|
April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Jérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Cancer
|
June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Nathalie Rippinger, Christine Fischer, Markus W Haun, et al.
British Journal of Cancer
|
March 6, 2015
Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes
C P Kratz, L Franke, H Peters, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 77) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 77 results.
International Journal of Cancer
|
March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
Jens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Annals of Hematology
|
July 8, 2003
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
H Goldschmidt, P Sonneveld, F W Cremer, et al.
Oncogene
|
March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
Karène Mahtouk, Dirk Hose, Thierry Rème, et al.
Leukemia
|
March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield
I Breitkreutz, H M Lokhorst, M S Raab, et al.
Blood
|
April 14, 2005
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Jérôme Moreaux, Friedrich W Cremer, Thierry Reme, et al.
Cancer
|
June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Nathalie Rippinger, Christine Fischer, Markus W Haun, et al.
British Journal of Cancer
|
March 6, 2015
Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes
C P Kratz, L Franke, H Peters, et al.
Page
of 8